NEW YORK (TheStreet) -- RATINGS CHANGES
Barrick Gold (ABX) was downgraded at Deutsche Bank to hold from buy. Company's ability to deleverage in low gold environment is a concern, Deutsche Bank said.
Must Read: Warren Buffett's Top 10 Dividend Stocks
Watch the video below for more of Monday's analysts' actions:
American Tower (AMT) was downgraded at Goldman Sachs to neutral. Valuation call, based on a 12-month price target of $106, Goldman said.
TD Ameritrade (AMTD) was upgraded at Citigroup to buy. Twelve-month price target is $40. Company has best organic growth in the group, Citigroup said.
Alliant Techsystems (ATK) was downgraded at RBC Capital to sector perform from outperform. Twelve-month price target is $125. Sporting outlook is weaker and the fate of the Orbital Sciences (ORB) merger is less clear, RBC Capital said.
BlackRock (BLK) was upgraded at Citigroup to buy. Twelve-month price target is $385. Company will likely gain market share from PIMCO and deserves a higher multiple, Citigroup said.
Biomarin (BMRN) was upgraded at Wells Fargo to outperform from market perform. Company has multiple potential clinical catalysts in 2015, Wells Fargo said.
Crown Castle (CCI) was downgraded at Nomura to neutral from buy. Valuation call, based on an $80 price target. Company is seeing lower growth but still offers an attractive dividend yield, Nomura said.
Crown Castle was upgraded at Goldman Sachs to buy. Twelve-month price target is $94. Company offers an attractive yield and growth potential, Goldman Sachs said.
Citizens Financial Group (CFG) was initiated with an equal-weight rating at Barclays. The 13th largest retail bank in U.S. has an attractive market share, the potential to drive meaningful returns, a strong balance sheet and a solid management team, Barclays said. Twelve-month price target is $26.
Rockwell Collins (COL) was upgraded at Wells Fargo to outperform. OEM business is growing and the company is buying back more stock, Wells Fargo said.
Ellie Mae (ELLI) was upgraded at JMP Securities to outperform from market perform. Twelve-month price target is $47. Company is positioned well for a recovery in growth for mortgage originations, JMP Securities said.